Sera of lung cancer patients affect the release of Th1, Th2 and monocyte-derived cytokines, and the expression of IL-2Rα by normal, stimulated mononuclear cells

Cellular and Molecular Biology Letters

Volumn 9, Issue 1, 2004, Pages 69-81

  Chechlińska, Magdalena ^a   Duma, Anna ^a   Świerkowska, Krystyna ^a   Kamińska, Janina ^a   Steffen, Jan ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Cancer Immunosuppression; Cytokine Imbalance; IL 2R; Th1; Th2

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CELL STIMULATION; CLINICAL ARTICLE; CYTOKINE RELEASE; DERIVATIZATION; FEMALE; HELPER CELL; HUMAN; HUMORAL IMMUNITY; LUNG CANCER; MACROPHAGE ACTIVATION; MALE; MONOCYTE; MONONUCLEAR CELL; PROTEIN EXPRESSION; TH1 CELL; TH2 CELL;

EID: 2342436144     PISSN: 14258153     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Bolton, P.M., Mander, A.M., Davidson, J.M., James, S.L., Newcombe, R.G. and Hughes, L.E. Cellular immunity in cancer: comparison of delayed hypersensitivity skin tests in three common cancers. Br. Med. J. 3 (1975) 18-20.
2. Evans, J.T., Goldrosen, M.H., Han, T., Mindowa, J., Howell, J., Mittelmann, A., Mingchu, T., and Holyoke, E.D. Cell-mediated immune status of colon cancer patients: evaluation by dermal antigen testing, measurment of lymphocyte stimulation and counts of peripheral blood rosette-forming cells. Cancer 40 (1977) 2716-2725.
3. Manson, L.A. Does antibody-dependent epitope masking permit progressive tumour growth in the face of cell-mediated cytotoxicity? Immunol. Today 12 (1991) 352-355.
4. Zembala, M., Mytar, B., Popiela, T. and Asherson, G.L. Depressed in vitro peripheral lymphocyte response to mitogens in cancer patients: the role of suppressor cells. Int. J. Cancer 19 (1977) 605-613.
5. Kavanaugh, D.Y. and Carbone, D.P. Immunologic dysfunction in cancer. Hematol. Oncol. Clin. North Am. 10 (1996) 927-951.
6. Dean, J.H., Connor, R., Herberman, R.B., Silva, J., McCoy, J.L. and Oldham, R.K. The relative proliferation index as a more sensitive parameter for evaluating lymphoproliferative responses of cancer patients to mitogens and alloantigens. Int. J. Cancer 2 (1977) 359-370.
7. Fritze, D. and Dystant, P. Detection of impaired mitogen responses in autologous whole blood of cancer patients using an optimized method of lymphocyte stimulation. Immunol. Lett. 8 (1984) 243-247.
8. Mantovani, G., Maccio, A., Melis, G., Mura, L., Massa, E. and Mudu, M.C. Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha-lipoic acid and N-acetyl cysteine. Int. J. Cancer 86 (2000) 842-847.
9. Abbas, A.K., Murphy, K.M. and Sher, A. Functional diversity of helper T lymphocytes. Nature 383 (1996) 787-793.
10. Elsässer-Beile, U., Kölble, N., Grussenmeyer, T., Schultze-Seemann, W., Wetterauer, U., Gallati, H., Schulte Mönting, J. and von Kleist, S. Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas. Tumor Biol. 19 (1998) 470-476.
11. +T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol. Immunother. 42 (1996) 1-8.
12. Sato, M., Goto, S., Kaneko, R., Ito, M., Sato, S. and Takeuchi, S. Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients. Anticancer Res. 18 (1998) 3951-3955.
13. Elsässer-Beile, U., von Kleist, S., Sauther, W., Gallati, H. and Schulte Mönting, J. Impaired cytokine production in whole blood cell cultures of patients with gynecological carcinomas in different clinical stages. Br. J. Cancer 68 (1993) 32-36.
14. Goto, S., Sato, M., Kaneko, R., Itoh, M., Sato, S. and Takeuchi, S. Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cell as a parameter of immunological dysfunction in advanced cancer patients. Cancer Immunol. Immunother. 48 (1999) 435-442.
15. Elsässer-Beile, U., von Kleist, S., Stähle, W., Schurhammer-Fuhrhmann, C., Schulte Mönting, J. and Gallati, H. Cytokine levels in whole blood as parameters of the cellular immunologic activity in patients with malignant melanoma and basal cell carcinoma. Cancer 71 (1993) 231-236.
16. Shurin, M.R., Lu, L., Kalinski, P., Stewart-Akers, A.M. and Lotze, M.T. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin. Immunopathol. 21 (1999) 339-359.
17. Shibata, M., Nezu, T., Kanou, H., Abe, H., Takekawa, M. and Fukuzawa, M. Decreased production of interleukin-12 and type 2 immune responses are marked in cachectic patients with colorectal and gastric cancer. J. Clin. Gastroenter. 34 (2002) 416-420.
18. Onishi, T., Ohishi, Y., Goto, H., Tomita, M. and Abe, K. An assessment of the immunological status of patients with renal cell carcinoma based on the relative abundance of T-helper 1- and -2 cytokine-producing CD4+ cells in peripheral blood. B. J. U. Int. 87 (2001) 755-759.
19. Nishimura, T., Iwakabe, K., Sekimoto, M., Ohmi, Y., Yahata, T., Nakui, M., Sato, T., Habu, S., Tashiro, H., Sato, M. and Ohta, A. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190 (1999) 617-627.
20. Nishimura, T., Nakui, M., Sato, M., Iwakabe, K., Kitamura, H., Sekimoto, M., Ohta, A., Koda, T. and Nishimura, S. The critical role of Th-1 dominant immunity in tumor immunology. Cancer Chemother. Pharmacol. 46 (2000) S52-61.
21. Chechlińska, M., Antczak, A. and Dȩbski, R. Interleukin-10 (IL-10), interleukin-1 receptor antagonist (IL-1ra) and soluble IL-2 receptor alpha (sIL-2Rα) in ascitic and cystic fluids from patients with malignant and benign ovarian tumours. Med. Sci. Monit. 2 (Suppl. 2) (1996) 207-210.
22. Gotlieb, W.H., Abrams, J.S., Watson, J.M., Velu, T.J., Berek, J.S. and Martinez-Maza, O. Presence of interleukin 10 (IL-10) in the ascites of patients with ovarian and other intra-abdominal cancers. Cytokine 4 (1992) 385-390.
23. Barton, D.P.J., Blanchard, D.K., Michelini-Norris, B., Nicosia, S.V., Cavanagh, D. and Djeu, J.Y. High serum and ascitic soluble interleukin-2 receptor α levels in advanced epithelial ovarian cancer. Blood 81 (1993) 424-429.
24. Hess, A.D., Gall, S.A. and Dawson, J.R. Inhibition of in vitro lymphocyte function by cyst and ascitic fluids from ovarian cancer patients. Cancer Res. 39 (1979) 2381-2389.
25. Berghella, A.M., Pellegrini, P., Del Beato, T., Marini, M., Tomei, E., Adorno, D. and Casciani, C.U. The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from Th1 to Th2 and back. Cancer Immunol. Immunother. 45 (1998) 241-249.
26. Fortis, C., Foppoli, M., Gianotti, L., Galli, L., Citterio, G., Consogno, G., Gentilini, O. and Braga, M. Increased interleukin-10 serum levels in patients with solid tumors. Cancer Lett. 104 (1996) 1-5.
27. De Vita, F., Orditura, M., Galizia, G., Romano, C., Infusino, S., Auriemma, A., Lieto, E. and Catalano, G. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies. Cancer 86 (1999) 1936-1943.
28. Iwagaki, H., Hizuta, A. and Tanaka, N. Interleukin-1 receptor antagonists and other markers in colorectal cancer patients. Scand. J. Gastroenterol. 32 (1997) 577-581.
29. Viviani, S., Camerini, E., Bonfante, V., Santoro, A., Balzarotti, M., Fornier, M., Devizzi, L., Verderio, P., Valagussa, P. and Bonadonna, G. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications. Br. J. Cancer 77 (1998) 992-997.
30. Siwicki, J.K., Hedberg, Y., Nowak, R., Loden, M., Zhao, J., Landberg, G. and Roos, G. Long-term cultured IL-2-dependent T cell lines demonstrate p16(INK4a) overexpression, normal pRb/p53, and upregulation of cyclins E or D2. Exp. Gerontol. 35 (2000) 375-88.
31. Wolf-Levin, R., Azuma, T., Aoki, K., Yagami, Y. and Okada, H. Specific IgG autoantibodies are potent inhibitors of autoreactive T cell response to phytohemagglutinin-activated T cells. J. Immunol. 151 (1993) 5864-5877.
32. Curtiss, L.K. and Edgington, T.S. Regulatory serum lipoproteins: regulation of lymphocyte stimulation by a species of low density lipoprotein. J. Immunol. 116 (1976) 1452-1458.
33. Elliott, L., Brooks, W. and Roszman, T. Role of interleukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect observed in mitogen-stimulated lymphocytes from patients with gliomas. J. Natl. Cancer Inst. 78 (1987) 919-922.
34. Asselin-Paturel, C., Echchakir, H., Carayol, G., Gay, F., Opolon, P., Grunewald, D., Chouiaib, S. and Mami-Chouiaib, F. Quantitative analysis of Th1, Th2 and TGFβ1 cytokine expression in tumour, TIL and PBL of non-small cell lung cancer patients. Int. J. Cancer 77 (1998) 7-12.
35. Roussel, E., Gingras, M.C., Grimm, E.A., Bruner, J.M. and Moser, R.P. Predominance of a type 2 intratumoral immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin. Exp. Immunol. 105 (1996) 344-352.
36. + T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. Cell. Immunol. 150 (1993) 114-123.
37. Onishi, T., Onishi, Y., Imagava, K., Ohmoto, and Y. Murata, K. An assessment of the immunological environment based on intratumoral cytokine production in renal cell carcinoma. B. J. U. Int. 83 (1999) 488-492.
38. Tatsumi, T., Kierstead, L.S., Ranieri, E., Gesualdo, L., Schena, F.P., Finke, J.H., Bukowski, R.M., Mueller-Berghaus, J., Kirkwood, J.M., Kwok, W.W. and Storkus, W.J. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J. Exp. Med. 196 (2002) 619-628.
39. Ghosh, P., Komschlies, K.L., Cippitelli, M., Longo, D.L., Subleski, J., Ye, J., Sica, A., Young, H.A., Wiltrout, R.H. and Ochoa, A.C. Gradual loss of T helper-1 populations in spleen of mice during progressive tumor growth. J. Natl. Cancer Inst. 87 (1995) 1478-1483.
40. Botti, C., Seregni, E., Ferrari, L., Martinetti, A. and Bombardieri, E. Immunosuppressive factors: role in cancer development and progression. Int. J. Biol. Markers 13 (1998) 51-69.
41. nd edition, Acad. Press Ltd., 1994, 223-237.
42. Dinarello, C.A. Biologic basis for interleukin-1 in disease. Blood 87 (1996) 2095-2147.
43. Rubin, L.A. and Nelson, D.L. The soluble interleukin-2 receptor: biology, function and clinical application. Ann. Intern. Med. 113 (1990) 619-627.
44. Hsieh, C.L., Chen, D.S. and Hwang, L.H. Tumor-induced immunosuppression: A barrief to immunotherapy of large tumors by cytokine secreting tumor vaccine. Hum. Gene Ther. 11 (2000) 681-692.
45. Sumitomo, M., Tachibana, M., Murai, M., Hayakawa, M., Nakamura, H., Takayanagi, A. and Shimizu, N. Overexpression of IL-1ra gene up-regulates interleukin-1β converting enzyme (ICE) gene expression: possible mechanism underlying IL-1β resistance of cancer cells. Br. J. Cancer 81 (1999) 277-286.
46. Yamamura, M., Modlin, R.L., Ohmen, J.D. and Moy, R.L. Local expression of antiinflammatory cytokines in cancer. J. Clin. Invest. 91 (1993) 1005-1010.
47. von Biberstein, S.E., Spiro, J.D., Lindquist, R. and Kreutzer, D.L. Interleukin-1 receptor antagonist in head and neck squamous cell carcinoma. Arch. Otolaryngol. 122 (1996) 751-759.